1420852-13-6 Usage
Uses
Used in Pharmaceutical Synthesis:
Tert-butyl 3-(1-aMinoethyl)azetidine-1-carboxylate is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the formation of complex molecular structures. The presence of the aminoethyl group allows for further chemical reactions, making it a versatile building block in medicinal chemistry.
Used in Organic Compounds Synthesis:
In the field of organic chemistry, tert-butyl 3-(1-aMinoethyl)azetidine-1-carboxylate is utilized as a reagent or precursor for the synthesis of various organic compounds. Its unique structure facilitates the creation of new molecules with potential applications in different industries.
Used in Drug Development:
Due to its potential as a building block for new drugs and bioactive compounds, tert-butyl 3-(1-aMinoethyl)azetidine-1-carboxylate is used in drug development for exploring its properties and reactivity in creating novel therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 1420852-13-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,2,0,8,5 and 2 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1420852-13:
(9*1)+(8*4)+(7*2)+(6*0)+(5*8)+(4*5)+(3*2)+(2*1)+(1*3)=126
126 % 10 = 6
So 1420852-13-6 is a valid CAS Registry Number.
1420852-13-6Relevant articles and documents
SOMATOSTATIN MODULATORS AND USES THEREOF
-
Paragraph 00251; 00253; 00260; 00262, (2019/08/29)
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
PYRROLOPYRAZINE KINASE INHIBITORS
-
Page/Page column 200, (2013/03/28)
The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.
